Association of Circulating Very Long-Chain Saturated Fatty Acids With Cardiovascular Mortality in National Health and Nutrition Examination Survey (NHANES) 2003-2004, 2011-2012
An erratum to this article was published (J Clin Endocrinol Metab, 18 Jan 2024 ↗)
Authors' conclusion
Our results confirm the protective effect of high levels of circulating VLSFAs (C22:0 and C24:0) on CVD, CHD, and all causes of death in the whole, hyperlipidemia, and hypertensive populations.
Study context
- Population
- Individuals from NHANES 2003–2004, 2011–2012; mortality via National Death Index; hyperlipidemia (n 1326) and hypertensive (n 1456) subpopulations
- Participants
- 4,132 individuals
- Exposure
- Higher vs lower circulating C22:0 and C24:0
- Outcome
- All-cause, CVD and coronary heart disease (CHD) mortality
Methodological detailsNHANES 2003-2004, 2011-2012, Cox regression
- NHANES 2003-2004, 2011-2012
- Cox regression
Main finding
As reported in the abstract
Mortality by higher circulating VLSFAs, whole population
- All-cause mortality, C22:0: HR (95% CI 0.271-0.618)
- .409
- All-cause mortality, C24:0: HR
- 0.430 (95% CI 0.283-0.651)
- Cardiovascular disease (CVD) mortality, C22:0: HR
- 0.286 (95% CI 0.134-0.612)
- CVD mortality, C24:0: HR
- 0.233 (95% CI 0.101-0.538)
- CHD mortality, C22:0: HR
- 0.401 (95% CI 0.187-0.913)
- CHD mortality, C24:0: HR
- 0.263 (95% CI 0.082-0.846)
Observational data: associations, not effects.
Further findings
- Higher C22:0 and C24:0 also protective for all-cause, CHD and CVD mortality in hyperlipidemia and hypertensive populations
Original publication
Association of Circulating Very Long-Chain Saturated Fatty Acids With Cardiovascular Mortality in NHANES 2003-2004, 2011-2012. J Clin Endocrinol Metab. Published 21 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →